ImpediMed Investor Relations Material
Latest events
Q3 2025 TU
ImpediMed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImpediMed Limited
Access all reports
ImpediMed Limited is an Australian medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive health assessments. The company’s primary products focus on the early detection, monitoring, and management of lymphedema, as well as body composition and fluid status assessments. ImpediMed’s technology is used in healthcare settings to support patient care in oncology, renal health, and other medical fields where fluid management is critical. ImpediMed Limited is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Key slides for ImpediMed Limited
Q2 2025 TU
ImpediMed Limited
Q3 2025 TU
ImpediMed Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IPD
Country
🇦🇺 Australia